FratFiles

• Save Paper

Company:
Biopure's greatest strength lies in its ability to market its blood substitute technology for both animal and human use. Further, Biopure has the patents and FDA approval to forge ahead in the animal market with a two-to-five year time buffer from new competition (using similar technology). One of the company's weaknesses is that it has not received FDA approval on Hemopure, and there are two other companies that could beat Biopure to the market with similar products. But if the FDA does not approve Hemopure, which could have the potential to cripple a single product biopharmaceutical company, the company may still withstand such a disruption with Oxyglobin sales and future research and development. Another weakness is the uncertainty of market acceptance for Hemopure, in the face of a deeply-rooted blood donation network.

Biopure has the potential to lead the market with blood substitutes for human and animal use. With Hemopure on the fringe of FDA approval, one......

View the rest of this paper...

Approximate Word Count: 1956
Approximate Pages: 8 (250 words per double-spaced page)

Similar Essays

1. Biopure Oxyglobin Launch
   

   Biopure Oxyglobin Launch. Company: Biopure's greatest strength lies in its ability
   to market its blood substitute technology for both animal and human use. ...

2. Biopure
   

   ... Biopure Corporation Based on the review, we recommend the Biopure Corporation to
   launch their animal blood substitute, Oxyglobin, immediately in the market, so ...

3. Biopure
   

   ... Biopure just received FDA approval for commercial release of Oxyglobin as a veterinary
   blood substitute. ... As Oxyglobin is planned to launch at $150 per ...

4. Biopure
   

   ... BIOPURE PAPER Recommendation: I strongly recommend that Biopure launch Oxyglobin
   immediately at a price of $150.00 and initially focus principally on large ...

5. Biopure Swot Analysis
   

   ... The main issue that is plaguing Biopure is how the possible launch of Oxyglobin
   will affect the future launch and pricing strategies of Hemopure, which could ...